問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



National Taiwan University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 2,600

    Total Beds

  • 1,008

    Total Doctors

  • linsinjie@ntuh.gov.tw
  • 100Taipei CityJhong Jheng7 Chung Shan S. Rd.,Zhongzheng

Recruiting Trial

1,450Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

3348Cases

2013-09-03 - 2020-06-30

Phase I/II

A Phase I/II trial of TLC399 (ProDex) in Patients with Macular Edema due to Retinal Vein Occlusion (RVO): An Open-label, Sequential Dose Escalation Phase I Part to Determine Maximum Tolerated Dose (MTD) and Dose Limiting Toxicities (DLTs) Followed by a Single-masked, Randomized Part to Evaluate Efficacy and Tolerability

  • Condition/Disease

    Macular Edema due to Retinal Vein Occlusion (RVO)

  • Test Drug

    TLC399 (ProDex)

Participate Sites
7Sites

Terminated7Sites

2016-01-01 - 2020-03-31

Phase IV

A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients with Peripheral T-cell Lymphoma after Prior Therapy

  • Condition/Disease

    Peripheral T-cell Lymphoma

  • Test Drug

    FOLOTYN Solution for intravenous injection

Participate Sites
11Sites

Terminated11Sites

2022-02-01 - 2028-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-07-01 - 2024-05-13

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-08-01 - 2025-06-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2009-12-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2008-09-01 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2018-04-03 - 2019-04-30

Phase I

A Phease1, Multicenter, Open-Label, Single Sequence Crossover Study to Evaluate Drug-Drug Interaction Potential of OATP1B/CYP3A Inhibitor on The Pharmacokinetics of DS-8201a in Subjects with HER2-Expressing Advanced Solid Malignant Tumors 一項第一期、多中心、開放標示、單一順序交叉試驗，評估在HER2表現型晚期實質惡性腫瘤受試者中，OATP1B/CYP3A抑制劑對DS-8201a藥物動力學發生藥物交互作用的可能性

  • Condition/Disease

    Advanced Solid Malignant Tumors

  • Test Drug

    DS-8201a

Participate Sites
3Sites

Terminated3Sites

2018-04-01 - 2019-09-30

Phase I

Phase 1, Multicenter, Open-label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2-Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer

  • Condition/Disease

    Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer

  • Test Drug

    DS-8201a

Participate Sites
2Sites

Terminated2Sites

趙毅
Taipei Veterans General Hospital

2015-03-01 - 2017-05-31

Phase III

An Asian, Phase III, multicenter, randomized, double-blind, placebo-controlled, 14-week trial to evaluate the efficacy of DS-5565 in patients with diabetic peripheral neuropathy pain (DPNP), followed by a 52-week open period Mark the extension test.

  • Condition/Disease

    Diabetic peripheral neuropathy pain

  • Test Drug

    DS-5565

Participate Sites
17Sites

Terminated17Sites

1 308 309 310 311 312 335
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB